ArticleCureus2024
Chronic Administration of Recombinant Human Erythropoietin Induces Angiogenesis in Healthy Mouse Brain.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The hematopoietic growth factor erythropoietin (EPO) plays an important role in apoptosis and oxidative stress attenuation as well as the promotion of angiogenesis in several tissues. Systemically administered EPO has beneficial effects on rabbits subjected to subarachnoid hemorrhage or stroke. So far, the angiogenic effect of EPO has been documented after an experimentally induced stroke or subarachnoid hemorrhage. In our study, we examined the possible angiogenic effect of chronic treatment with recombinant human erythropoietin (rHuEPO) under normal conditions, in an attempt to clarify if the existence of a lesion or oxygen deprivation is necessary to initiate the angiogenic effect of EPO. Materials & methods BALB/c mice were used and were divided into three groups as follows: group A (no treatment), group B (saline only), and group C (7000 U rHuEPO per week for three weeks by intraperitoneal injection). The number of CD31- and CD34-positive endothelial cells was assessed in mouse brain preparations under control conditions and after treatment with rHuEPO. Results There was no difference between the mean numbers of CD31 and CD34 cells among the different groups. The mean number of vessels in group A and group B was almost the same (18 ± 2 vessels per optical field). However, the number of brain vessels in group C (EPO treatment) increased significantly by 44% compared to controls (26 ± 4 vessels per optical field, P < 0.05). Conclusion These data indicate that no lesion or oxygen deprivation is needed to initiate the angiogenic effect of EPO in healthy mouse brains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.